When do you offer radioembolization (Y90) in the treatment of unresectable HCC?
Should Y90 be offered before or after TACE (based on the Northwestern phase 2 study) or sorafenib (based on the SARAH trial)?
Answer from: Radiation Oncologist at Community Practice
Y90 does have some more data of better LC than TACE but not with OS in the Brown meta analysis (Brown et al., PMID 35943116). I think for small tumors less than 5 cm, Y90 can be appropriate. I would not treat it for PVTT. The SARAH trial had a large majority with PVTT and was negative. As were ...
Sign in or Register to read more